Northern Trust Corp Buys 39,424 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Northern Trust Corp grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 568,389 shares of the biopharmaceutical company's stock after acquiring an additional 39,424 shares during the period. Northern Trust Corp owned 0.60% of Ultragenyx Pharmaceutical worth $20,581,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical during the first quarter worth approximately $57,000. Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical during the first quarter worth approximately $59,000. Covestor Ltd lifted its position in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after acquiring an additional 795 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $82,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RARE has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Guggenheim reaffirmed a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded up $0.73 during mid-day trading on Friday, reaching $32.01. The stock had a trading volume of 831,937 shares, compared to its average volume of 1,298,130. The stock has a 50-day simple moving average of $30.49 and a two-hundred day simple moving average of $34.94. The stock has a market capitalization of $3.08 billion, a PE ratio of -5.79 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm's quarterly revenue was up 13.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.